Bayer Cancer Drug Can Be Combined with Other Drugs

	Tweet

Bayer AG’s key experimental anti-cancer drug BAY 43-9006 can be combined with other anti-cancer agents, according to results from a Phase I trial, the German drugs and chemicals group said on Tuesday.

Bayer said data from Phase I safety and metabolism studies showed the drug could be given with anti-cancer agents doxorubicin, oxaliplatin, fluorouracil and leucovorin.

In addition, the drug—being developed with Onyx Pharmaceuticals—needed no dose adjustment when given with ketoconazole. Safety data from all studies showed no unexpected treatment-related adverse events, it said.

The trial results were presented at the European Society of Medical Oncology meeting in Vienna.

BAY 43-9006 is in Phase III trials for the treatment of advanced kidney cancer, and Bayer and Onyx intend to initiate additional Phase II and III trials in other tumor types.

Analysts say the drug could fetch as much as 500 million euros ($635 million) in peak annual sales.

It is vital for Bayer, whose drugs unit has been hit by a poor pipeline, generic competition to antibiotic Cipro and a $1 billion-plus recall of its anti-cholesterol drug Baycol.

Bayer shares were up 0.9 percent at 22.75 euros at 1451 GMT, outperforming a 0.3 percent rise in the DAX bluechip index.

RELATED STORIES:
Aspirin doesn’t lead to false-positive stool tests   Newer flu drugs more effective than old   Chinese scientists develop bird flu vaccine - media   Bone-boosting drug helps very elderly women   FDA Says Heart Warning Added to Pfizer’s Bextra   Clamor for obesity pill may test FDA limits   ‘Da Vinci Diet’ Digs Carbs   Use Caution Buying Medical Products Online   Viagra packages to include anti-counterfeit tags   Roswell Park research aids development of myeloma drug   With Vioxx gone, pain drug prices jump   FDA to Establish New Drug Oversight Board

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]